Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CALCNYSE:CHRONASDAQ:DARENASDAQ:EGRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCALCCalciMedica$1.80+5.3%$1.78$1.43▼$6.02$23.89M1.2445,805 shs3,846 shsCHROChromocell Therapeutics$0.97+1.3%$1.30$0.45▼$3.80$6.40M4.59435,106 shs16,308 shsDAREDaré Bioscience$2.90$2.92$2.67▼$6.24$25.67M1.236,315 shs17,685 shsEGRXEagle Pharmaceuticals$2.00+11.1%$1.65$1.50▼$2.13$25.97M0.8311,382 shs1,001 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCALCCalciMedica+7.08%-10.00%+17.65%-23.40%-66.54%CHROChromocell Therapeutics+1.57%-3.00%-29.20%-42.26%-41.57%DAREDaré Bioscience0.00%+0.35%-3.65%-8.52%-39.58%EGRXEagle Pharmaceuticals+11.11%+3.09%+1.52%+34.23%-47.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCALCCalciMedica2.0034 of 5 stars3.55.00.00.00.01.70.0CHROChromocell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADAREDaré Bioscience1.3897 of 5 stars3.33.00.00.02.00.00.0EGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCALCCalciMedica 3.00Buy$18.00900.00% UpsideCHROChromocell Therapeutics 3.00BuyN/AN/ADAREDaré Bioscience 2.50Moderate Buy$12.00313.79% UpsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CHRO, DARE, CALC, and EGRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025DAREDaré BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/4/2025CALCCalciMedicaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCALCCalciMedicaN/AN/AN/AN/A$1.42 per shareN/ACHROChromocell TherapeuticsN/AN/AN/AN/A($1.65) per shareN/ADAREDaré Bioscience$25.91K990.58N/AN/A($0.61) per share-4.75EGRXEagle Pharmaceuticals$257.55M0.10$5.00 per share0.40N/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCALCCalciMedica-$34.36M-$1.56N/AN/AN/AN/A-164.24%-103.53%8/11/2025 (Estimated)CHROChromocell Therapeutics-$7.38M-$1.24N/A∞N/AN/AN/A-453.90%N/ADAREDaré Bioscience-$30.16M-$0.17N/AN/AN/A-191.65%N/A-18.98%8/11/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/ALatest CHRO, DARE, CALC, and EGRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025CALCCalciMedica-$0.43-$0.36+$0.07-$0.36N/AN/A5/13/2025Q1 2025DAREDaré Bioscience-$0.63-$0.50+$0.13-$0.50$0.60 million$0.03 million3/31/2025Q4 2024DAREDaré Bioscience-$0.66-$0.64+$0.02-$0.64$1.00 million($0.06) million3/27/2025Q4 2024CALCCalciMedica-$0.48-$0.34+$0.14-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCALCCalciMedicaN/AN/AN/AN/AN/ACHROChromocell TherapeuticsN/AN/AN/AN/AN/ADAREDaré BioscienceN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCALCCalciMedicaN/A4.154.15CHROChromocell TherapeuticsN/A0.600.60DAREDaré BioscienceN/A1.141.14EGRXEagle PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCALCCalciMedicaN/ACHROChromocell Therapeutics77.96%DAREDaré Bioscience6.70%EGRXEagle Pharmaceuticals85.36%Insider OwnershipCompanyInsider OwnershipCALCCalciMedica41.55%CHROChromocell Therapeutics16.40%DAREDaré Bioscience4.00%EGRXEagle Pharmaceuticals28.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCALCCalciMedica3013.97 million7.88 millionNo DataCHROChromocell Therapeutics46.60 million5.04 millionN/ADAREDaré Bioscience308.85 million8.35 millionNot OptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataCHRO, DARE, CALC, and EGRX HeadlinesRecent News About These CompaniesStockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)May 18, 2025 | americanbankingnews.comEagle Pharmaceuticals Insider Trading Activity | OTC:EGRX | BenzingaApril 28, 2025 | benzinga.comEagle Pharmaceuticals announces $69M pact to monetize Bendeka royaltiesApril 1, 2025 | markets.businessinsider.comEagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® RoyaltiesMarch 31, 2025 | markets.businessinsider.comEagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights PlanMarch 21, 2025 | globenewswire.comEagle Pharma Founder Sues Company to Recoup Cost of SEC InvestigationNovember 23, 2024 | law.comEagle Pharmaceuticals to Delist from NasdaqNovember 19, 2024 | investing.comEagle Announces Update on Delisting from Nasdaq and SEC DeregistrationNovember 15, 2024 | globenewswire.comEagle Pharmaceuticals Appoints New CFO Amid Leadership ChangeNovember 12, 2024 | markets.businessinsider.comEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanNovember 1, 2024 | finanznachrichten.deEagle Pharmaceuticals Implements Stockholder Rights PlanNovember 1, 2024 | markets.businessinsider.comEagle Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanOctober 31, 2024 | markets.businessinsider.comUnion Square Park Capital Management's Strategic Acquisition of Eagle Pharmaceuticals SharesOctober 8, 2024 | gurufocus.comWhy Did Eagle Pharmaceuticals Inc (EGRX) Stock Plunge -77.22% Last Week?October 7, 2024 | bovnews.comEagle Pharmaceuticals (NASDAQ:EGRX) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comEagle Pharmaceuticals IncSeptember 28, 2024 | money.usnews.comIs Eagle Materials Inc. (EXP) the Best Stock Pick You Need to Know in Jim Cramer’s Latest Watchlist?September 15, 2024 | msn.comEagle Pharmaceuticals receives another delisting noticeSeptember 3, 2024 | njbiz.comEagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqAugust 27, 2024 | globenewswire.comEagle Pharmaceuticals, Inc.: Eagle Pharmaceuticals Announces Receipt of Delisting Notification from NasdaqMay 22, 2024 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?3 Stocks Just Announced Intentions to Buyback Near 10% of SharesBy Leo Miller | April 28, 2025View 3 Stocks Just Announced Intentions to Buyback Near 10% of SharesCHRO, DARE, CALC, and EGRX Company DescriptionsCalciMedica NASDAQ:CALC$1.80 +0.09 (+5.26%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.80 0.00 (0.00%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Chromocell Therapeutics NYSE:CHRO$0.97 +0.01 (+1.35%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.96 -0.01 (-1.13%) As of 05/23/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.Daré Bioscience NASDAQ:DARE$2.90 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.87 -0.03 (-1.17%) As of 05/23/2025 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.Eagle Pharmaceuticals NASDAQ:EGRX$2.00 +0.20 (+11.11%) As of 05/23/2025 03:10 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
